Seeking Alpha
 

LipoScience (LPDX)

- NASDAQ
LPDX is defunct.
  • Sep. 25, 2014, 12:45 PM
    | Sep. 25, 2014, 12:45 PM | Comment!
  • Sep. 25, 2014, 9:17 AM
    | Sep. 25, 2014, 9:17 AM | Comment!
  • Mar. 28, 2014, 12:45 PM
    | Mar. 28, 2014, 12:45 PM | Comment!
  • Mar. 28, 2014, 9:12 AM
    | Mar. 28, 2014, 9:12 AM | 3 Comments
  • Sep. 6, 2013, 11:29 AM
    • LipoScience (LPDX +2%) appoints William Cromwell, M.D., as the company's chief medical officer.
    • He joins LPDX for a second time, having previously served in the same position from 1999 - 2005.
    • Cromwell replaces Robert M Honigberg, who announced last month that he was resigning effective September 17 for family-related reasons.
    | Sep. 6, 2013, 11:29 AM | Comment!
  • Aug. 2, 2013, 3:08 PM
    • LipoScience (LPDX -10.7%) plummets as CEO Richard Brajer steps down "to pursue other interests."
    • Robert Greczyn is named interim CEO.
    • The company says Q2 revenues will likely come in at $13.3M, towards the low end of guidance. Consensus is $13.6M
    • For the full year, the company cuts its revenue guidance to $52-54M, down from $54-56M, and below Street estimates of $55.37M. (PR)
    | Aug. 2, 2013, 3:08 PM | Comment!
  • Aug. 2, 2013, 12:45 PM
    | Aug. 2, 2013, 12:45 PM | Comment!
  • May 22, 2013, 12:40 PM
    LipoScience (LPDX +3.4%) trades up today after announcing the availability of its NMR lipoprotein particle testing using the Vantera Clinical Analyzer through Mayo Medical Laboratories. The analysis provides physicians and patients with a detailed assessment of cardiovascular disease risk from a single blood test that measures the concentration of low-density lipoprotein particles and other lipoprotein information.
    | May 22, 2013, 12:40 PM | Comment!
  • May 10, 2013, 12:52 PM
    Midday top 10 gainers: UNIS +58%. DRAM +57%. VRML +26%. SREV +22%. MCP +20%. UBNT +18%. RH +18%. WCRX +17%. CSIQ +16%. SQNM +16%.
    Midday top 10 losers: PTIE -48%. DRRX -41%. IFMI -34%. AFFY -26%. SRT -23%. LPDX -22%. OPTR -17%. REFR -16%. PANL -16%. TRMD -15%.
    | May 10, 2013, 12:52 PM | Comment!
  • May 10, 2013, 12:34 PM
    LipoScience (LPDX -22.8%) tanks after CEO Richard Brajer expresses his dissatisfaction with the company's revenue performance in Q1 (-1.2% Y/Y). LipoProfile test order growth fell to 8.7% Y/Y versus Y/Y growth of 14.8% in Q4, although orders did rise Q/Q. The main problems — which include difficulties ramping up new sales reps, faster direct business-to-lab partner conversion, and managed care headwinds — "cannot be fixed overnight," Brajer laments. In light of this, LPDX lowers its FY13 revenue guidance to $54-56M (consensus is $61.43M). (PR)
    | May 10, 2013, 12:34 PM | Comment!
  • Feb. 19, 2013, 1:51 PM
    LipoScience (LPDX +0.6%) moves up after Piper Jaffray initiates the shares with an Overweight and a $15.00 price target. Piper notes that ongoing traction converting its LDL-C patient monitoring assays to LDL-P and represents a potential $330M annual revenue run-rate, which would exceed both its top and bottom-line projections. Separately, Barclay's and UBS also initiated coverage with an Overweight and Buy, respectively.
    | Feb. 19, 2013, 1:51 PM | Comment!
Visit Seeking Alpha's
Company Description
LipoScience Inc is a clinical diagnostic company. The Company focuses on new field of personalized diagnostics based on nuclear magnetic resonance or NMR technology.